Homepage Top Section2

The collaboration will combine FogPharma’s Helicon peptide platform with ARTBIO’s AlphaDirect platform to create targeted therapies using the 212Pb isotope. The companies will jointly develop HEARTs against multiple

The company initially acquired the site in 2022 and extensively renovated it. The Bronx facility is equipped with latest technology and marks a significant investment by PharmaLogic in

The funding attracted a diverse group of new investors, including Cormorant Asset Management, SymBiosis, Surveyor Capital, Walleye Capital, Laurion Capital Management, Tetragon Financial Group, LG Technology Ventures, Cantor

This expansion, announced by New York Governor Kathy Hochul, is supported by New York State through the state’s economic development agency, Empire State Development (ESD).  The state government

The collaboration is set to address the issue of relapse in patients undergoing treatment with conventional anti-CD19 CAR T-cell therapies through the use of TriCAR-T immunotherapy. As per

The funding round was led jointly by ARTIS Ventures and Wing VC, with contributions from a consortium of investors including Alexandria Venture Investments, Fusion Fund, OMX Ventures, Civilization

The BLA seeks approval for the use of subcutaneous nivolumab as a monotherapy, as maintenance therapy after treatment with Opdivo plus Yervoy (ipilimumab) combination regimen, or along with

The financing round is co-led by 8VC and DCVC Bio, with contributions from Samsung Life Science Fund, The Children’s Hospital of Philadelphia Foundation, Benjamin Franklin Technology Partners, Modi

According to Korea Biomedical Review (KBR), the company’s flagship autoimmune disease treatment, called ‘Remsima’, has secured a substantial tender from the Peruvian Workers’ Insurance System (EsSalud).  This tender